Oncopharmpod
Adjuvant Pembrolizumab (NSCLC), Elacestrant, & Pirtobrutinib
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:17:58
- Mas informaciones
Informações:
Sinopsis
First - despite what you'll hear - it is pirTobrutinib, not pirobrutinib. Second - lots of great information on the current state of targeted therapies in adjuvant NSCLC and on two exciting new drugs: elacestrant and pirtobrutinib.
